Citable company snapshot
REGENERON PHARMACEUTICALS, INC.'s latest SEC-sourced 2026-03-31 period shows $3.61B in revenue and $727.20M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 31, 2026 | $3.61B | $3.88B | -7.2% |
| xbrl:OperatingIncomeLoss | Mar 31, 2026 | $642.90M | $879.90M | -26.9% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $727.20M | $844.60M | -13.9% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 31, 2026 | $1.08B | $1.17B | -7.8% |
| Free Cash Flow (computed) | Mar 31, 2026 | $848.30M | $922.00M | -8.0% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed Apr 29, 2026; accession 0000872589-26-000016.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
